

# Supplementary Documents [IFRS]

## Financial results for the fiscal year 2022 (FY2022)

### Astellas Pharma Inc.

- FY2022 Financial Results
  - For the year ended March 31, 2023
  - Three months ended March 31, 2023
- Pipeline list

#### Cautionary Notes

*In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.*

**[For the year ended March 31, 2023]**

1. Consolidated Results (Full Basis)

Unit: B¥

	FY21 Full Year	FY22 Full Year	Change	Change (%)
Revenue	1,296.2	1,518.6	222.5	17.2%
Cost of sales	253.0	288.4	35.3	14.0%
Ratio to Revenue	19.5%	19.0%		
Gross profit	1,043.2	1,230.3	187.1	17.9%
SG&A expenses	548.8	630.3	81.4	14.8%
Ratio to Revenue	42.3%	41.5%		
XTANDI co-promotion fee in the United states	139.3	175.5	36.2	26.0%
Personnel expenses	191.4	211.4	20.0	10.4%
Advertising and Sales Promotion and Other	218.1	243.4	25.3	11.6%
R&D expenses	246.0	276.1	30.1	12.2%
Ratio to Revenue	19.0%	18.2%		
Amortisation of intangible assets	28.3	38.4	10.2	35.9%
Gain on divestiture of intangible assets	24.2	0.2	-24.0	-99.1%
Share of profit (loss) of investments accounted for using equity method	0.5	1.3	0.8	157.8%
Other income	15.3	3.6	-11.6	-76.1%
Net foreign exchange gains	8.2	-	-8.2	-
Fair value remeasurements on contingent consideration	5.4	2.3	-3.0	-56.5%
Other expenses	104.3	157.5	53.2	51.0%
Impairment losses	74.9	84.6	9.7	13.0%
Restructuring costs	19.6	4.5	-15.0	-76.9%
Net foreign exchange losses	-	10.1	10.1	-
Fair value remeasurements on contingent consideration	7.0	53.1	46.0	652.7%
Operating profit	155.7	133.0	-22.7	-14.6%
Ratio to Revenue	12.0%	8.8%		
Finance income	6.1	8.1	2.0	31.9%
Finance expenses	4.9	8.8	3.8	77.4%
Profit before tax	156.9	132.4	-24.5	-15.6%
Ratio to Revenue	12.1%	8.7%		
Income tax expense	32.8	33.6	0.8	2.6%
Profit	124.1	98.7	-25.4	-20.4%
Ratio to Revenue	9.6%	6.5%		
Comprehensive income	208.1	205.3	-2.8	-1.4%

Forecasts		Change from FY22	
FY22 Full Year	FY23 Full Year	FY23 Full Year	Change (%)
1,529.0	1,520.0	1,520.0	0.1%
642.0	661.0	661.0	4.9%
42.0%	43.5%	43.5%	0.3%
186.0	176.0	176.0	-9.1%
278.0	251.0	251.0	-9.1%
18.2%	16.5%	16.5%	-9.1%
137.0	288.0	288.0	116.5%
9.0%	18.9%	18.9%	116.5%
135.0	289.0	289.0	118.3%
8.8%	19.0%	19.0%	118.3%
105.0	227.0	227.0	130.0%
6.9%	14.9%	14.9%	130.0%

2. Consolidated Results (Core Basis)

Unit: B¥

	FY21 Full Year	FY22 Full Year	Change	Change (%)
Revenue	1,296.2	1,518.6	222.5	17.2%
Cost of sales	253.0	288.4	35.3	14.0%
Ratio to Revenue	19.5%	19.0%		
Gross profit	1,043.2	1,230.3	187.1	17.9%
SG&A expenses	548.8	630.3	81.4	14.8%
Ratio to Revenue	42.3%	41.5%		
XTANDI co-promotion fee in the United states	139.3	175.5	36.2	26.0%
Personnel expenses	191.4	211.4	20.0	10.4%
Advertising and Sales Promotion and Other	218.1	243.4	25.3	11.6%
R&D expenses	246.0	276.1	30.1	12.2%
Ratio to Revenue	19.0%	18.2%		
Amortisation of intangible assets	28.3	38.4	10.2	35.9%
Gain on divestiture of intangible assets	24.2	0.2	-24.0	-99.1%
Share of profit (loss) of investments accounted for using equity method	0.5	1.3	0.8	157.8%
Operating profit	244.7	286.9	42.2	17.2%
Ratio to Revenue	18.9%	18.9%		
Finance income	6.1	8.1	2.0	31.9%
Finance expenses	4.9	8.8	3.8	77.4%
Profit before tax	245.9	286.2	40.3	16.4%
Ratio to Revenue	19.0%	18.8%		
Income tax expense	55.4	61.6	6.3	11.3%
Profit	190.6	224.6	34.0	17.9%
Ratio to Revenue	14.7%	14.8%		

Forecasts

FY22 Full Year
1,529.0
642.0
42.0%
186.0
278.0
18.2%
290.0
19.0%
223.0
14.6%

Forecasts  
Change from  
FY22

FY23 Full Year	Change (%)
1,520.0	0.1%
661.0	4.9%
43.5%	0.3%
176.0	
251.0	-9.1%
16.5%	
290.0	1.1%
19.1%	
228.0	1.5%
15.0%	

3. Exchange Rate

Unit: yen

	FY21 Ave.	FY22 Ave.	FY21 End	FY22 End
USD/Yen	112	135	122	133
EUR/Yen	131	141	135	144

Forecasts

FY22 Full Year
137
139

Forecasts

FY23 Full Year
130
140

\* Fx impacts: Revenue +164.4 billion yen and Core operating profit +40.1 billion yen

4. Reconciliation of Full Basis to Core Basis

Unit: B¥

	FY21 Full year			FY22 Full year		
	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
<b>Revenue</b>	<b>1,296.2</b>	-	<b>1,296.2</b>	<b>1,518.6</b>	-	<b>1,518.6</b>
Cost of sales	253.0	-	253.0	288.4	-	288.4
<b>Gross profit</b>	<b>1,043.2</b>	-	<b>1,043.2</b>	<b>1,230.3</b>	-	<b>1,230.3</b>
SG&A expenses	548.8	-	548.8	630.3	-	630.3
R&D expenses	246.0	-	246.0	276.1	-	276.1
Amortisation of intangible assets	28.3	-	28.3	38.4	-	38.4
Gain on divestiture of intangible assets	24.2	-	24.2	0.2	-	0.2
Share of profit (loss) of investments accounted for using equity method	0.5	-	0.5	1.3	-	1.3
Other income *	15.3	-15.3	-	3.6	-3.6	-
Other expenses *	104.3	-104.3	-	157.5	-157.5	-
<b>Operating profit</b>	<b>155.7</b>	<b>89.1</b>	<b>244.7</b>	<b>133.0</b>	<b>153.9</b>	<b>286.9</b>
Finance income	6.1	-	6.1	8.1	-	8.1
Finance expenses	4.9	-	4.9	8.8	-	8.8
<b>Profit before tax</b>	<b>156.9</b>	<b>89.1</b>	<b>245.9</b>	<b>132.4</b>	<b>153.9</b>	<b>286.2</b>
Income tax expense	32.8	22.6	55.4	33.6	28.0	61.6
<b>Profit</b>	<b>124.1</b>	<b>66.5</b>	<b>190.6</b>	<b>98.7</b>	<b>125.9</b>	<b>224.6</b>

\* "Other income" and "Other expenses" are excluded from Core basis results.

"Other income" and "Other expenses" include gain/loss on sale and disposal of property, plant and equipment, impairment losses, restructuring costs, litigation costs and foreign exchange gains/losses, etc.

## 5. Revenue by Region

Unit: B¥

	FY21 Full Year	FY22 Full Year	Change	Change (%)
Revenue	1,296.2	1,518.6	222.5	17.2%
Japan	258.8	262.3	3.5	1.4%
Ratio to Revenue	20.0%	17.3%		
United States	537.5	652.4	115.0	21.4%
Ratio to Revenue	41.5%	43.0%		
Established Markets	306.5	358.4	51.9	16.9%
Ratio to Revenue	23.6%	23.6%		
Greater China	66.3	80.0	13.7	20.7%
Ratio to Revenue	5.1%	5.3%		
International Markets	118.7	144.7	26.0	21.9%
Ratio to Revenue	9.2%	9.5%		
Others	8.4	20.7	12.3	146.5%
Ratio to Revenue	0.6%	1.4%		

- Established Markets: Europe, Canada

- Greater China: China, Hong Kong, Taiwan

- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Australia, Export sales, etc.

- From FY2022, the commercial segment of Australia was changed From Established Markets to International Markets. All figures above reflect this change.

Forecasts		Change from FY22	
FY22 Full Year	FY23 Full Year	FY23 Full Year	Change (%)
1,529.0	1,520.0	1,520.0	0.1%
264.4	278.6	278.6	6.2%
17.3%	18.3%	18.3%	
680.8	655.3	655.3	0.4%
44.5%	43.1%	43.1%	
356.3	364.5	364.5	1.7%
23.3%	24.0%	24.0%	
80.2	78.1	78.1	-2.3%
5.2%	5.1%	5.1%	
133.2	137.7	137.7	-4.9%
8.7%	9.1%	9.1%	
14.1	5.7	5.7	-72.3%
0.9%	0.4%	0.4%	

## 6. Per Share Information

	FY21 Full Year	FY22 Full Year
The number of shares issued (thousand)	1,835,851	1,809,663
Treasury Shares (thousand)	8,777	12,900
The number of shares issued after deducting Treasury Shares (thousand)	1,827,073	1,796,762
Earnings per share (yen)	67.08	54.24
Earnings per share (yen) core basis	103.03	123.42
Dividend per share (yen)	50	60
Return on Equity (%)	8.7%	6.7%
Dividend on Earnings (%)	6.5%	7.3%

- The numbers of shares are presented by disregarding any number of shares less than the specified units.

Forecasts		Forecasts	
FY22 Full Year	FY23 Full Year	FY23 Full Year	FY23 Full Year
57.47	126.34	126.34	
122.05	126.89	126.89	
60	70	70	

## 7. Investment in Property, Plant and Equipment

### Depreciation/Amortisation

Unit: B¥

	FY21 Full Year	FY22 Full Year	Change	Change (%)
Investment in Property, Plant and Equipment	30.2	36.6	6.4	21.2%
Depreciation (PP&E)	40.1	40.0	-0.0	-0.1%
Amortisation of Intangible Assets (incl. software, etc.)	39.6	65.7	26.1	65.8%

- Investment in Property, Plant and Equipment does not include right-of-use asset.

Forecasts		Change from FY22	
FY22 Full Year	FY23 Full Year	FY23 Full Year	Change (%)
37.0	39.0	39.0	6.7%
40.0	43.0	43.0	7.4%
67.0	48.0	48.0	-27.0%

8. Sales of major products

1) Global

Unit: B¥

	FY21 Full Year	FY22 Full Year	Change	Change (%)
XTANDI	534.3	661.1	126.8	23.7%
United States	276.9	341.8	64.8	23.4%
ex-US	257.4	319.3	62.0	24.1%
Japan	47.2	54.7	7.6	16.0%
Established Markets	166.3	197.9	31.6	19.0%
Greater China	7.9	11.1	3.1	39.7%
International Markets	36.0	55.6	19.7	54.8%
PADCEV	21.7	44.4	22.7	104.4%
Japan	1.8	8.4	6.6	377.8%
United States	19.5	29.2	9.6	49.3%
Established Markets	0.5	6.8	6.3	-
International Markets	-	0.1	0.1	-
XOSPATA	34.1	46.6	12.5	36.7%
Japan	3.9	4.3	0.4	10.7%
United States	18.9	25.5	6.6	35.1%
Established Markets	9.0	12.1	3.0	33.4%
Greater China	1.5	2.5	0.9	58.8%
International Markets	0.7	2.2	1.5	225.5%
EVRENZO	2.6	3.2	0.6	23.0%
Japan	2.5	2.4	-0.1	-3.3%
Established Markets	0.1	0.6	0.5	476.4%
International Markets	-	0.2	0.2	-
Betanis/Myrbetriq/BETMIGA	172.3	188.6	16.3	9.5%
Japan	37.5	33.5	-4.0	-10.6%
United States	87.2	96.5	9.3	10.7%
Established Markets	35.2	42.8	7.7	21.8%
Greater China	2.9	3.9	1.0	35.0%
International Markets	9.6	11.8	2.2	23.4%
Prograf	185.4	198.8	13.4	7.2%
Japan	38.2	35.6	-2.6	-6.8%
United States	9.4	10.7	1.3	14.2%
Established Markets	65.3	69.3	3.9	6.0%
Greater China	38.1	46.8	8.7	22.8%
International Markets	34.3	36.3	2.0	5.9%
Vesicare	22.0	15.9	-6.1	-27.7%

	FY22 Full Year	Forecasts FY23 Full Year	Change from FY22 Change (%)
	670.0	669.9	1.3%
	358.8	342.6	0.2%
	311.2	327.3	2.5%
	55.4	58.2	6.3%
	195.5	198.7	0.4%
	12.3	14.5	30.9%
	48.0	55.9	0.4%
	45.4	66.7	50.1%
	8.3	9.9	17.6%
	31.5	44.3	52.1%
	5.5	11.5	68.9%
	0.1	0.9	887.0%
	45.8	49.3	6.0%
	4.0	4.1	-4.6%
	25.3	26.7	4.4%
	11.9	13.0	7.8%
	2.5	2.2	-11.9%
	2.1	3.4	54.4%
	5.0	8.0	150.2%
	3.5	2.8	17.7%
	1.2	4.0	538.8%
	0.3	1.2	609.7%
	195.0	179.5	-4.8%
	33.1	29.7	-11.4%
	104.1	90.7	-6.0%
	42.6	44.8	4.7%
	3.8	2.7	-31.6%
	11.3	11.6	-1.7%
	200.3	187.9	-5.5%
	35.5	30.0	-15.7%
	11.0	10.2	-5.3%
	71.0	67.8	-2.1%
	46.1	45.8	-2.2%
	36.8	34.1	-6.3%
	15.3	13.5	-14.7%

- Sales of products in Japan are shown in a gross sales basis.

- Established Markets: Europe, Canada

- Greater China: China, Hong Kong, Taiwan

- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Australia, Export sales, etc.

- From FY2022, the commercial segment of Australia was changed from Established Markets to International Markets. All figures above reflect this change.

- PADCEV (United States): Co-promotion revenue from Seagen

- Astellas' EVRENZO territories: Japan, Europe, the Commonwealth of Independent States, Middle East, South Africa, etc.

2) Revenue by region

(1) Japan

Unit: B¥

<Global>	FY21 Full Year	FY22 Full Year	Change	Change (%)
XTANDI	47.2	54.7	7.6	16.0%
PADCEV	1.8	8.4	6.6	377.8%
XOSPATA	3.9	4.3	0.4	10.7%
EVRENZO	2.5	2.4	-0.1	-3.3%
Betanis	37.5	33.5	-4.0	-10.6%
Prograf (Including Gracaptor)	38.2	35.6	-2.6	-6.8%
Vesicare	10.0	3.9	-6.1	-60.9%
Harnal	2.6	1.8	-0.8	-29.8%
Funguard	1.6	1.1	-0.5	-30.2%

Forecasts FY22 Full Year
55.4
8.3
4.0
3.5
33.1
35.5
3.6
1.7
1.2

Forecasts FY23 Full Year	Change from FY22 Change (%)
58.2	6.3%
9.9	17.6%
4.1	-4.6%
2.8	17.7%
29.7	-11.4%
30.0	-15.7%
2.8	-29.4%
1.3	-29.5%
0.2	-82.1%

<Main products>

Suglat [Family]	30.3	30.3	0.1	0.3%
Sujanu	12.5	12.3	-0.1	-1.0%
Repatha	5.8	6.4	0.6	11.0%
Linzess	6.9	7.0	0.1	1.7%
BLINCYTO	6.4	7.9	1.5	23.8%
EVENTY	31.4	42.1	10.7	34.1%
Smyraf	2.4	2.5	0.1	4.6%
Vaccines	5.1	5.5	0.3	6.1%
Gonax	5.0	4.7	-0.3	-5.9%
Cimzia	11.2	11.2	0.1	0.7%
Myslee	7.0	5.8	-1.2	-17.6%
Total Rx Sales In Japanese market	256.9	260.1	3.1	1.2%

31.5
7.3
2.9
7.6
5.1
5.9
262.3

29.7	-2.1%
7.3	4.0%
2.7	10.4%
5.1	-5.9%
4.3	-26.5%
277.5	6.7%

- Sales of products in Japan are shown in a gross sales basis.

## (2) United States

Unit: M\$

	FY21 Full Year	FY22 Full Year	Change	Change (%)
Revenue	4,782	4,816	34	0.7%
XTANDI	2,464	2,523	59	2.4%
PADCEV	174	215	41	23.9%
XOSPATA	168	188	20	12.0%
Myrbetriq	775	712	-63	-8.2%
Prograf	84	79	-4	-5.3%
Vesicare	15	5	-9	-63.5%
MYCAMINE	48	21	-27	-56.2%
AmBisome	135	118	-16	-12.0%
CRESEMBA	194	228	34	17.3%
Lexiscan	725	725	-0	-0.0%

Forecasts

FY22 Full Year
4,968
2,618
230
185
760
80
6
20
106
217
724

Forecasts  
Change from  
FY22

FY23 Full Year	Change (%)
5,041	4.7%
2,635	4.4%
341	58.5%
205	8.8%
698	-2.0%
78	-1.3%
6	11.7%
5	-78.0%
128	8.2%
291	27.7%
274	-62.1%

## (3) Established Markets

Unit: M€

	FY21 Full Year	FY22 Full Year	Change	Change (%)
Revenue	2,348	2,544	196	8.3%
XTANDI	1,274	1,405	130	10.2%
PADCEV	4	48	45	-
XOSPATA	69	86	16	23.6%
EVRENZO	1	4	4	434.1%
BETMIGA	269	304	35	12.9%
Prograf	501	492	-9	-1.7%
Vesicare	39	38	-1	-2.9%
Omnice	65	64	-1	-0.8%
MYCAMINE	21	15	-5	-25.5%

Forecasts

FY22 Full Year
2,557
1,403
40
85
9
306
509
38
63
15

Forecasts  
Change from  
FY22

FY23 Full Year	Change (%)
2,604	2.4%
1,419	1.1%
82	70.0%
93	8.5%
29	542.9%
320	5.3%
485	-1.5%
36	-5.0%
67	3.6%
3	-77.6%

- Established Markets: Europe, Canada

- From FY2022, the commercial segment of Australia was changed from Established Markets to International Markets. All figures above reflect this change.



(4) Greater China

Unit: B¥

	FY21 Full Year	FY22 Full Year	Change	Change (%)
Revenue	66.3	80.0	13.7	20.7%
XTANDI	7.9	11.1	3.1	39.7%
XOSPATA	1.5	2.5	0.9	58.8%
BETMIGA	2.9	3.9	1.0	35.0%
Prograf	38.1	46.8	8.7	22.8%
Vesicare	1.0	1.0	-0.0	-2.6%
Harnal	8.2	8.2	0.0	0.3%
MYCAMINE	2.9	2.5	-0.5	-16.3%
Feburic	2.9	3.4	0.5	16.5%

Forecasts

FY22 Full Year
80.2
12.3
2.5
3.8
46.1
1.1
8.5
2.1
3.1

Forecasts Change from  
FY22

FY23 Full Year	Change (%)
78.1	-2.3%
14.5	30.9%
2.2	-11.9%
2.7	-31.6%
45.8	-2.2%
1.0	-5.1%
8.4	1.8%
0.3	-88.4%
2.7	-19.0%

- Greater China: China, Hong Kong, Taiwan

(5) International Markets

Unit: B¥

	FY21 Full Year	FY22 Full Year	Change	Change (%)
Revenue	118.7	144.7	26.0	21.9%
XTANDI	36.0	55.6	19.7	54.8%
PADCEV	-	0.1	0.1	-
XOSPATA	0.7	2.2	1.5	225.5%
EVRENZO	-	0.2	0.2	-
BETMIGA	9.6	11.8	2.2	23.4%
Prograf	34.3	36.3	2.0	5.9%
Vesicare	4.1	4.9	0.8	18.7%
Harnal	16.5	18.6	2.1	12.9%
MYCAMINE	6.3	5.6	-0.6	-10.4%

Forecasts

FY22 Full Year
133.2
48.0
0.1
2.1
0.3
11.3
36.8
4.5
17.3
5.8

Forecasts Change from  
FY22

FY23 Full Year	Change (%)
137.7	-4.9%
55.9	0.4%
0.9	887.0%
3.4	54.4%
1.2	609.7%
11.6	-1.7%
34.1	-6.3%
4.0	-18.2%
17.5	-6.1%
1.1	-80.1%

- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Australia, Export sales, etc.

- From FY2022, the commercial segment of Australia was changed from Established Markets to International Markets. All figures above reflect this change.

## 9. Consolidated statements of financial position

Unit: B¥

	FY21 End	FY22 End	Change
<b>Assets</b>	<b>2,332.4</b>	<b>2,456.5</b>	<b>124.1</b>
<b>Non-current assets</b>	<b>1,409.0</b>	<b>1,406.6</b>	<b>-2.5</b>
Property, plant and equipment	269.0	286.5	17.4
Goodwill	303.0	328.4	25.4
Intangible assets	623.4	562.5	-60.9
Trade and other receivables	29.8	24.2	-5.6
Investments accounted for using equity method	10.0	12.7	2.7
Deferred tax assets	72.3	84.2	11.8
Other financial assets	91.8	97.9	6.0
Other non-current assets	9.5	10.3	0.7
<b>Current assets</b>	<b>923.4</b>	<b>1,050.0</b>	<b>126.6</b>
Inventories	153.1	174.4	21.3
Trade and other receivables	382.5	428.0	45.5
Income tax receivable	21.5	17.8	-3.7
Other financial assets	21.3	19.8	-1.5
Other current assets	29.0	32.4	3.4
Cash and cash equivalents	316.0	376.8	60.9
Assets held for sale	-	0.7	0.7

Unit: B¥

	FY21 End	FY22 End	Change
<b>Equity and Liabilities</b>	<b>2,332.4</b>	<b>2,456.5</b>	<b>124.1</b>
<b>Equity</b>	<b>1,460.3</b>	<b>1,508.0</b>	<b>47.6</b>
<b>Equity attributable to owners of the parent</b>	<b>1,460.3</b>	<b>1,508.0</b>	<b>47.6</b>
Share capital	103.0	103.0	-
Capital surplus	179.5	181.3	1.8
Treasury shares	-13.9	-25.1	-11.2
Retained earnings	944.3	908.2	-36.1
Other components of equity	247.5	340.6	93.1
<b>Liabilities</b>	<b>872.1</b>	<b>948.6</b>	<b>76.5</b>
<b>Non-current liabilities</b>	<b>184.7</b>	<b>222.5</b>	<b>37.9</b>
Trade and other payables	0.7	4.2	3.5
Deferred tax liabilities	5.8	6.0	0.2
Retirement benefit liabilities	37.2	24.8	-12.4
Provisions	5.8	6.5	0.7
Other financial liabilities	95.9	139.9	44.0
Other non-current liabilities	39.2	41.0	1.8
<b>Current liabilities</b>	<b>687.4</b>	<b>726.0</b>	<b>38.6</b>
Trade and other payables	130.7	140.2	9.5
Income tax payable	32.4	5.1	-27.3
Provisions	16.6	17.9	1.3
Other financial liabilities	185.0	180.1	-4.8
Other current liabilities	322.8	382.7	59.9

10. Employees

Number of employees

	FY21 End	FY22 End
Total	14,522	14,484

11. Shareholders

	FY21 End	FY22 End
Banks	38.4%	39.6%
Securities	4.6%	5.0%
Other companies	3.2%	3.1%
Foreign companies	45.5%	43.3%
Individuals and others	8.2%	8.9%
Treasury Stock*	0.0%	0.0%

\* Treasury Stock does not include shares owned by the executive compensation BIP (Board Incentive Plan) trust and ESOP (Employee Stock Ownership Plan) trust.

**[Three months ended March 31, 2023]**

1. Consolidated Results (Full Basis)

Unit: B¥

	FY22							
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Revenue	381.8	17.1%	380.4	16.9%	402.2	18.1%	354.3	16.6%
Cost of sales	88.9	42.8%	62.8	0.4%	74.4	7.3%	62.3	5.7%
Ratio to Revenue	23.3%		16.5%		18.5%		17.6%	
Gross profit	292.9	11.0%	317.6	20.8%	327.8	20.8%	292.0	19.2%
SG&A expenses	153.4	11.9%	154.6	15.9%	163.0	19.9%	159.3	11.8%
Ratio to Revenue	40.2%		40.6%		40.5%		45.0%	
XTANDI co-promotion fee in the United states	43.1	25.1%	46.5	27.1%	48.6	29.2%	37.3	21.6%
Personnel expenses	51.2	4.5%	53.6	14.0%	51.5	9.5%	55.1	13.9%
Advertising and Sales Promotion and Other	59.1	10.1%	54.4	9.4%	62.9	22.7%	66.9	5.5%
R&D expenses	74.0	26.9%	65.2	7.3%	66.9	14.1%	70.1	2.5%
Ratio to Revenue	19.4%		17.1%		16.6%		19.8%	
Amortisation of intangible assets	10.7	80.2%	9.2	43.7%	9.2	17.0%	9.3	15.3%
Gain on divestiture of intangible assets	0.2	-	0.0	-	0.0	-99.9%	0.0	-95.9%
Share of profit (loss) of investments accounted for using equity method	0.3	19.8%	1.4	-	-0.4	-	-0.1	-
Other income	16.3	-	0.2	-91.4%	1.1	-64.7%	4.2	-67.1%
Net foreign exchange gains	14.1	-	-	-	-	-	-	-
Fair value remeasurements on contingent consideration	1.5	-	0.1	-	0.9	-59.2%	3.9	-19.0%
Other expenses	38.4	41.7%	3.6	-67.2%	28.0	50.3%	105.7	106.8%
Impairment losses	22.0	-15.4%	0.7	-	1.6	134.3%	60.3	25.2%
Restructuring costs	0.0	-99.1%	1.1	-43.9%	0.4	-97.2%	3.0	135.7%
Net foreign exchange losses	-	-	0.2	-	20.6	-	3.4	-
Fair value remeasurements on contingent consideration	15.8	-	0.1	-98.8%	4.0	-	37.2	-
Operating profit	33.1	-8.2%	86.7	60.4%	61.4	-22.5%	-48.2	-
Ratio to Revenue	8.7%		22.8%		15.3%		-13.6%	
Finance income	0.9	-36.3%	3.6	725.8%	1.2	181.1%	2.4	-36.4%
Finance expenses	2.4	39.6%	1.5	20.2%	2.8	115.2%	2.1	207.2%
Profit before tax	31.7	-11.6%	88.8	66.7%	59.8	-23.7%	-47.9	-
Ratio to Revenue	8.3%		23.3%		14.9%		-13.5%	
Income tax expense	6.9	33.5%	17.2	39.3%	11.4	-34.9%	-1.8	-
Profit	24.8	-19.1%	71.6	75.0%	48.4	-20.5%	-46.1	-
Ratio to Revenue	6.5%		18.8%		12.0%		-13.0%	
Comprehensive income	134.4	271.2%	109.3	222.7%	-25.2	-	-13.3	-

## 2. Consolidated Results (Core Basis)

Unit: B¥

		FY22							
		APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
		(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Revenue		381.8	17.1%	380.4	16.9%	402.2	18.1%	354.3	16.6%
Cost of sales		88.9	42.8%	62.8	0.4%	74.4	7.3%	62.3	5.7%
	Ratio to Revenue	23.3%		16.5%		18.5%		17.6%	
Gross profit		292.9	11.0%	317.6	20.8%	327.8	20.8%	292.0	19.2%
SG&A expenses		153.4	11.9%	154.6	15.9%	163.0	19.9%	159.3	11.8%
	Ratio to Revenue	40.2%		40.6%		40.5%		45.0%	
	XTANDI co-promotion fee in the United states	43.1	25.1%	46.5	27.1%	48.6	29.2%	37.3	21.6%
	Personnel expenses	51.2	4.5%	53.6	14.0%	51.5	9.5%	55.1	13.9%
	Advertising and Sales Promotion and Other	59.1	10.1%	54.4	9.4%	62.9	22.7%	66.9	5.5%
R&D expenses		74.0	26.9%	65.2	7.3%	66.9	14.1%	70.1	2.5%
	Ratio to Revenue	19.4%		17.1%		16.6%		19.8%	
	Amortisation of intangible assets	10.7	80.2%	9.2	43.7%	9.2	17.0%	9.3	15.3%
	Gain on divestiture of intangible assets	0.2	-	0.0	-	0.0	-99.9%	0.0	-95.9%
	Share of profit (loss) of investments accounted for using equity method	0.3	19.8%	1.4	-	-0.4	-	-0.1	-
Operating profit		55.3	-12.0%	90.1	44.2%	88.3	-6.8%	53.2	115.5%
	Ratio to Revenue	14.5%		23.7%		22.0%		15.0%	
Finance income		0.9	-36.3%	3.6	725.8%	1.2	181.1%	2.4	-36.4%
Finance expenses		2.4	39.6%	1.5	20.2%	2.8	115.2%	2.1	207.2%
Profit before Tax		53.8	-14.0%	92.1	49.5%	86.7	-7.7%	53.6	92.4%
	Ratio to Revenue	14.1%		24.2%		21.5%		15.1%	
Income tax expense		8.0	-40.1%	18.0	48.5%	17.7	-22.8%	17.9	157.4%
Profit		45.8	-6.9%	74.1	49.7%	68.9	-2.8%	35.7	70.7%
	Ratio to Revenue	12.0%		19.5%		17.1%		10.1%	

### 3. Revenue by Region

Unit: B¥

		FY22							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Revenue		381.8	17.1%	380.4	16.9%	402.2	18.1%	354.3	16.6%
	Japan	66.8	-1.0%	66.5	5.5%	71.2	-2.0%	57.8	4.0%
	Ratio to Revenue	17.5%		17.5%		17.7%		16.3%	
	United States	160.9	20.4%	167.4	22.7%	172.8	25.4%	151.3	16.9%
	Ratio to Revenue	42.1%		44.0%		43.0%		42.7%	
	Established Markets	86.1	10.4%	88.7	17.7%	96.3	20.9%	87.3	18.7%
	Ratio to Revenue	22.6%		23.3%		24.0%		24.6%	
	Greater China	23.2	41.0%	21.9	31.5%	20.1	16.4%	14.9	-6.9%
	Ratio to Revenue	6.1%		5.7%		5.0%		4.2%	
	International Markets	34.4	23.7%	34.2	8.7%	36.6	22.5%	39.5	33.8%
	Ratio to Revenue	9.0%		9.0%		9.1%		11.2%	
	Others	10.4	273.9%	1.7	-32.8%	5.1	55.1%	3.5	-
	Ratio to Revenue	2.7%		0.4%		1.3%		1.0%	

- Established Markets: Europe, Canada

- Greater China: China, Hong Kong, Taiwan

- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Australia, Export sales, etc.

- From FY2022, the commercial segment of Australia was changed from Established Markets to International Markets. All figures above reflect this change.

### 4. Investment in Property, Plant and Equipment Depreciation/Amortisation

Unit: B¥

		FY22							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Investment in Property, Plant and Equipment		11.7	125.9%	5.8	-25.5%	7.1	-24.2%	12.0	53.2%
Depreciation (PP&E)		9.8	-0.8%	9.9	-0.4%	10.1	-3.7%	10.2	4.9%
Amortisation of Intangible Assets (incl. software, etc.)		27.0	228.9%	12.9	44.1%	12.9	16.8%	12.8	12.8%

- Investment in Property, Plant and Equipment does not include right-of-use asset.

5. Sales of major products

1) Global

Unit: B¥

		FY22							
		APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
		(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
XTANDI		162.4	22.2%	169.6	25.9%	179.8	24.9%	149.3	21.6%
	United States	83.9	22.7%	90.9	25.0%	94.3	26.4%	72.6	18.7%
	ex-US	78.5	21.6%	78.7	27.0%	85.5	23.3%	76.6	24.5%
	Japan	14.1	17.4%	13.4	15.9%	14.8	14.3%	12.5	16.7%
	Established Markets	46.8	9.3%	50.0	27.1%	53.1	20.9%	47.9	19.2%
	Greater China	3.6	90.2%	2.4	40.0%	3.8	104.6%	1.2	-49.3%
	International Markets	14.0	79.2%	12.8	38.1%	13.8	30.2%	15.0	82.1%
PADCEV		10.6	151.6%	10.2	107.6%	12.3	125.5%	11.4	58.6%
	Japan	2.0	-	2.0	-	2.3	325.7%	2.1	70.0%
	United States	7.3	74.8%	6.8	38.1%	7.8	61.0%	7.2	29.6%
	Established Markets	1.2	-	1.4	-	2.1	-	2.1	396.7%
	International Markets	-	-	0.0	-	0.1	-	0.0	-
XOSPATA		10.5	26.3%	13.0	58.8%	12.8	38.8%	10.3	23.0%
	Japan	1.1	5.7%	1.0	2.0%	1.2	22.9%	0.9	13.0%
	United States	5.9	29.5%	6.5	47.4%	7.6	41.4%	5.4	20.8%
	Established Markets	2.7	31.2%	2.9	36.8%	3.2	36.3%	3.3	29.5%
	Greater China	0.5	-12.7%	2.0	296.5%	0.0	-93.2%	0.0	-89.7%
	International Markets	0.3	170.0%	0.6	341.8%	0.7	394.5%	0.6	113.8%
EVRENZO		0.7	19.3%	0.8	0.6%	0.9	27.3%	0.8	58.5%
	Japan	0.7	8.1%	0.6	-10.9%	0.7	-4.7%	0.5	-5.1%
	Established Markets	0.1	-	0.1	29.9%	0.2	-	0.2	-
	International Markets	-	-	0.0	-	0.0	-	0.1	-
Betanis/Myrbetriq/BETMIGA		47.9	9.0%	45.5	12.5%	47.7	12.0%	47.5	4.8%
	Japan	9.3	-5.0%	8.2	-8.4%	8.9	-15.1%	7.2	-13.6%
	United States	24.7	8.3%	22.7	17.9%	23.1	16.0%	26.0	3.2%
	Established Markets	10.1	18.2%	10.7	22.6%	11.5	24.2%	10.5	22.0%
	Greater China	1.0	46.8%	1.0	56.2%	1.1	48.5%	0.9	0.1%
	International Markets	2.8	31.2%	3.0	1.3%	3.1	41.4%	2.9	26.9%
Prograf		51.8	14.6%	48.6	3.1%	51.3	5.0%	47.1	6.5%
	Japan	9.6	-6.0%	8.8	-6.3%	9.6	-9.8%	7.5	-4.3%
	United States	2.5	20.3%	2.6	-1.7%	3.1	10.1%	2.5	36.2%
	Established Markets	17.7	9.2%	17.2	0.8%	18.2	7.6%	16.3	6.9%
	Greater China	13.6	41.1%	11.8	19.6%	11.8	14.7%	9.6	15.4%
	International Markets	8.4	19.3%	8.1	0.3%	8.6	5.2%	11.2	2.1%
Vesicare		4.0	-45.4%	4.0	-24.6%	4.3	-17.4%	3.5	-12.7%

- Sales of products in Japan are shown in a gross sales basis.

- Established Markets: Europe, Canada

- Greater China: China, Hong Kong, Taiwan

- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Australia, Export sales, etc.

- From FY2022, the commercial segment of Australia was changed from Established Markets to International Markets. All figures above reflect this change.

- PADCEV (United States): Co-promotion revenue from Seagen

- Astellas' EVRENZO territories: Japan, Europe, the Commonwealth of Independent States, Middle East, South Africa, etc

2) Revenue by region

(1) Japan

Unit: B¥

<Global>	FY22							
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
XTANDI	14.1	17.4%	13.4	15.9%	14.8	14.3%	12.5	16.7%
PADCEV	2.0	-	2.0	-	2.3	325.7%	2.1	70.0%
XOSPATA	1.1	5.7%	1.0	2.0%	1.2	22.9%	0.9	13.0%
EVRENZO	0.7	8.1%	0.6	-10.9%	0.7	-4.7%	0.5	-5.1%
Betanis	9.3	-5.0%	8.2	-8.4%	8.9	-15.1%	7.2	-13.6%
Prograf (Including Gracaptor)	9.6	-6.0%	8.8	-6.3%	9.6	-9.8%	7.5	-4.3%
Vesicare	1.2	-73.9%	0.9	-52.2%	1.0	-50.9%	0.7	-45.6%
Harnal	0.5	-31.7%	0.5	-27.4%	0.5	-31.6%	0.4	-27.6%
Funguard	0.3	-29.0%	0.3	-33.5%	0.3	-30.7%	0.2	-26.0%

<Main products>

Suglat [Family]	8.0	2.1%	7.5	0.3%	8.2	-1.7%	6.6	0.5%
Sujanu	3.3	2.0%	3.1	-2.3%	3.3	-1.4%	2.7	-2.3%
Repatha	1.6	12.2%	1.6	10.8%	1.7	8.9%	1.5	12.2%
Linzess	1.8	3.9%	1.7	1.4%	1.9	-1.5%	1.6	3.6%
BLINCYTO	1.8	29.2%	2.0	29.0%	2.3	23.9%	1.9	14.4%
EVENITY	10.0	42.1%	10.1	35.9%	11.3	28.6%	10.7	31.5%
Smyraf	0.6	0.5%	0.6	7.7%	0.7	0.6%	0.5	11.9%
Vaccines	0.0	0.0%	3.2	63.2%	2.6	-18.7%	-0.4	526.4%
Gonax	1.3	-1.3%	1.2	-8.3%	1.3	-6.5%	1.0	-7.5%
Cimzia	3.0	4.2%	2.8	1.6%	3.1	-1.8%	2.4	-1.1%
Myslee	1.6	-14.5%	1.5	-16.1%	1.5	-20.8%	1.2	-19.0%
<b>Total Rx Sales In Japanese market</b>	<b>66.4</b>	<b>-0.9%</b>	<b>65.6</b>	<b>4.7%</b>	<b>70.8</b>	<b>-1.8%</b>	<b>57.3</b>	<b>3.7%</b>

- Sales of products in Japan are shown in a gross sales basis.



## (2) United States

Unit: M\$

		FY22							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Revenue		1,240	1.5%	1,209	-2.5%	1,222	0.9%	1,145	3.1%
	XTANDI	647	3.5%	657	-0.5%	668	1.7%	551	5.5%
	PADCEV	57	47.5%	49	9.3%	56	29.7%	54	13.4%
	XOSPATA	46	9.3%	47	17.4%	54	14.0%	41	7.0%
	Myrbetriq	190	-8.6%	163	-6.7%	163	-6.8%	196	-10.1%
	Prograf	19	1.5%	19	-21.9%	22	-11.3%	19	21.6%
	Vesicare	0	-119.1%	3	-47.8%	2	-61.0%	1	-55.0%
	MYCAMINE	6	-59.6%	5	-66.9%	5	-50.0%	4	-32.5%
	Ambisome	29	-4.9%	29	-24.3%	29	-11.9%	32	-4.8%
	CRESEMBA	53	15.5%	53	8.2%	55	14.5%	67	29.9%
	Lexiscan	194	-1.1%	183	-1.5%	169	0.1%	179	2.6%

## (3) Established Markets

Unit: M€

		FY22							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Revenue		624	5.5%	637	9.6%	669	9.3%	614	9.0%
	XTANDI	339	4.4%	359	18.3%	369	9.2%	337	9.5%
	PADCEV	9	-	10	-	15	-	15	357.5%
	XOSPATA	19	25.3%	21	27.6%	22	23.3%	23	19.1%
	EVRENZO	0	-	1	22.3%	2	-	1	-
	BETMIGA	73	12.9%	77	14.3%	80	12.3%	74	12.0%
	Prograf	128	4.3%	123	-6.1%	126	-3.0%	114	-1.9%
	Vesicare	10	-4.3%	9	-10.8%	9	7.0%	9	-2.1%
	Omnic	16	-3.8%	15	-10.8%	16	7.7%	16	5.2%
	MYCAMINE	5	-30.0%	3	-38.4%	4	-5.4%	3	-23.6%

- Established Markets: Europe, Canada

- From FY2022, the commercial segment of Australia was changed from Established Markets to International Markets. All figures above reflect this change.

## (4) Greater China

Unit: B¥

		FY22							
		APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
		(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Revenue		23.2	41.0%	21.9	31.5%	20.1	16.4%	14.9	-6.9%
	XTANDI	3.6	90.2%	2.4	40.0%	3.8	104.6%	1.2	-49.3%
	XOSPATA	0.5	-12.7%	2.0	296.5%	0.0	-93.2%	0.0	-89.7%
	BETMIGA	1.0	46.8%	1.0	56.2%	1.1	48.5%	0.9	0.1%
	Prograf	13.6	41.1%	11.8	19.6%	11.8	14.7%	9.6	15.4%
	Vesicare	0.3	4.2%	0.3	12.2%	0.3	-1.5%	0.2	-25.1%
	Harnal	2.4	20.3%	2.5	26.0%	1.8	-14.7%	1.5	-27.8%
	MYCAMINE	0.8	35.8%	0.8	14.8%	0.3	-58.4%	0.5	-42.3%
	Feburic	0.8	35.0%	0.9	23.4%	0.8	15.4%	0.8	-2.9%

- Greater China: China, Hong Kong, Taiwan

## (5) International Markets

Unit: B¥

		FY22							
		APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
		(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Revenue		34.4	23.7%	34.2	8.7%	36.6	22.5%	39.5	33.8%
	XTANDI	14.0	79.2%	12.8	38.1%	13.8	30.2%	15.0	82.1%
	PADCEV	-	-	0.0	-	0.1	-	0.0	-
	XOSPATA	0.3	170.0%	0.6	341.8%	0.7	394.5%	0.6	113.8%
	EVRENZO	-	-	0.0	-	0.0	-	0.1	-
	BETMIGA	2.8	31.2%	3.0	1.3%	3.1	41.4%	2.9	26.9%
	Prograf	8.4	19.3%	8.1	0.3%	8.6	5.2%	11.2	2.1%
	Vesicare	1.2	34.0%	1.2	-1.8%	1.4	18.1%	1.1	32.7%
	Harnal	4.3	-1.1%	4.8	22.4%	4.9	5.7%	4.5	29.2%
	MYCAMINE	1.5	-9.6%	1.5	-26.0%	1.3	18.1%	1.3	-10.7%

- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Australia, Export sales, etc.

- From FY2022, the commercial segment of Australia was changed from Established Markets to International Markets. All figures above reflect this change.

## R&D Pipeline

The list shows the development status in the target diseases for which we aim to obtain approval in Japan, the United States, Europe and/or China.

As of Apr 2023

Underlined items indicate changes from the previous announcement in Feb 2023.

### XTANDI and Strategic products (1/2)

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
enzalutamide MDV3100 (XTANDI)	Small molecule	Androgen receptor inhibitor	Metastatic castration-sensitive prostate cancer	China P-III	Pfizer	
			Non-metastatic castration-sensitive prostate cancer	P-III		
enfortumab vedotin ASG-22ME (PADCEV)	Antibody-drug conjugate (ADC)	Nectin-4 targeted ADC	Metastatic urothelial cancer, platinum-containing chemotherapy and PD-1/L1 inhibitor pretreated	<u>China</u> <u>Filed (Mar 2023)</u>	In-house [Co-development with Seagen]	
			Metastatic urothelial cancer, previously untreated (first line; cisplatin-ineligible, combo with pembrolizumab)	US <u>Approved (Apr 2023)</u>		
			Metastatic urothelial cancer, previously untreated (first line; combo with pembrolizumab)	P-III		
			Muscle-invasive bladder cancer (combo with pembrolizumab)	P-III		
			Other solid tumors	P-II		
			Non-muscle-invasive bladder cancer	P-I		
gilteritinib ASP2215 (XOSPATA)	Small molecule	FLT3 inhibitor	Post-chemotherapy maintenance acute myeloid leukemia	P-III	In-house	
			Post-hematopoietic stem cell transplant maintenance acute myeloid leukemia	P-III		
			Newly diagnosed acute myeloid leukemia with high intensity induction of chemotherapy	P-III		
			Newly diagnosed acute myeloid leukemia with low intensity induction of chemotherapy	P-I		
			Acute myeloid leukemia in pediatric patients	P-III		

**XTANDI and Strategic products (2/2)**

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensors **	Remarks
zolbetuximab IMAB362	Antibody	Anti-Claudin 18.2 monoclonal antibody	Gastric and gastroesophageal junction adenocarcinoma	P-III	In-house (Ganymed)	
			Pancreatic adenocarcinoma	P-II		
fezolinetant ESN364	Small molecule	NK3 receptor antagonist	Vasomotor symptoms due to menopause	US Filed (Aug 2022) Europe Filed (Sep 2022) China P-III Japan P-II	In-house (Ogeda)	
resamirigene bilparovect AT132	Gene therapy (AAV-based gene therapy)	MTM1 gene replacement to express myotubularin	X-linked myotubular myopathy	P-II	In-house (Audentes Therapeutics)	

\* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

\*\* Compounds with "In-house" in this column include ones discovered by collaborative research.

**Updates from the previous announcement (Feb 2023):**

**enfortumab vedotin:** Filed in China in Mar 2023 for locally advanced or metastatic urothelial cancer in patients who have received prior treatment with a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy. Obtained accelerated approval in US in Apr 2023 for unresectable locally advanced or metastatic urothelial cancer who are ineligible to receive cisplatin-based chemotherapy in the first-line setting.

Projects with Focus Area approach (1/2)

Primary Focus	Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensors **	Remarks
Immuno-oncology	ASP1570	Small molecule	DGKζ inhibitor	Cancer	P-I	In-house	
	ASP2138	Antibody	Anti-Claudin 18.2 and anti-CD3 bispecific antibody	Gastric and gastroesophageal junction adenocarcinoma, pancreatic adenocarcinoma	P-I	Xencor [Discovered through collaborative research]	
	ASP2074	Antibody	Bispecific antibody	Cancer	P-I	In-house	
	ASP1002	Antibody	Bispecific antibody	Cancer	P-I	In-house	
Blindness and Regeneration	ASP7317	Cell therapy	Retinal pigment epithelium cells	Geographic atrophy secondary to age-related macular degeneration, Stargardt disease	P-I	In-house (Ocata Therapeutics)	
Mitochondria	bocidelpar ASP0367/MA-0211	Small molecule	PPARδ modulator	Primary mitochondrial myopathies	P-II	In-house (Mitobridge)	
				Duchenne muscular dystrophy	P-I		

**Projects with Focus Area approach (2/2)**

Primary Focus	Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensors **	Remarks
Genetic regulation	resamirigene bilparvovec AT132 ***	Gene therapy (AAV-based gene therapy)	MTM1 gene replacement to express myotubularin	X-linked myotubular myopathy	P-II	In-house (Audentes Therapeutics)	
	AT845	Gene therapy (AAV-based gene therapy)	GAA gene replacement to express GAA enzyme	Pompe disease	P-I	In-house (Audentes Therapeutics)	
Targeted Protein Degradation	ASP3082	Small molecule	KRAS G12D degrader	Cancer	P-I	In-house	
(Other projects with Focus Area approach)	ASP0598	Recombinant protein	Recombinant human heparin-binding epidermal growth factor-like growth factor	Chronic tympanic membrane perforation	P-I	Auration Biotech	

\* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

\*\* Compounds with "In-house" in this column include ones discovered by collaborative research.

\*\*\* AT132 is also listed in "XTANDI and Strategic products".

**Updates from the previous announcement (Feb 2023):**

**ASP9801:** Discontinued the development for cancer in Phase 1.

**ASP7517:** Discontinued the development for acute myeloid leukemia and myelodysplastic syndrome in Phase 2. Discontinued the development for solid tumor in Phase 1.

**ASP0739:** Discontinued the development for cancer in Phase 1.

**ASP8731/ML-0207:** Discontinued the development for sickle cell disease in Phase 1.

**FX-322:** Discontinued the development for sensorineural hearing loss because Phase 2 study did not meet its primary endpoint.

## Others

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
mirabegron YM178	Small molecule	$\beta_3$ receptor agonist	Neurogenic detrusor overactivity in pediatric patients	Europe P-III	In-house	
			Overactive bladder in pediatric patients	Europe P-III		
peficitinib ASP015K	Small molecule	JAK inhibitor	Rheumatoid arthritis	China Filed (Aug 2022)	In-house	
isavuconazole	Small molecule	Azole antifungal	Invasive aspergillosis and mucormycosis in pediatric patients	US P-II	Basilea	
ASP8062	Small molecule	GABA <sub>B</sub> receptor positive allosteric modulator	Alcohol use disorder	P-I	In-house	

\* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

\*\* Compounds with "In-house" in this column include ones discovered by collaborative research.

## Rx+ Program

As of Apr 2023

Underlined items indicate changes from the previous announcement in Feb 2023.

Category	Program	Concept	Status*	Partner	Remarks
Digital health Other services	Fit-eNce	Service to provide scientifically evidenced exercise programs and systems supporting regular exercise	Under feasibility study		
	Fit-eNce Home	Service to provide scientifically evidenced exercise programs and systems supporting regular exercise at home	Under feasibility study		
	BlueStar	Digital therapeutics for adults with diabetes	Under clinical trial preparation	<u>Welldoc</u> <u>Roche Diabetes Care Japan</u>	
Drug-device combination	pudexacianinium chloride ASP5354	Intraoperative ureter visualization for use in patients undergoing minimally invasive and open abdominopelvic surgeries	P-III	<u>Stryker</u>	
		Visualization and localization of lymph nodes in patients with breast cancer or melanoma undergoing lymphatic mapping	P-II		

\* The list shows the most advanced stage if the stages are different depending on the region.

### Updates from the previous announcement (Feb 2023):

**BlueStar:** Added Roche Diabetes Care Japan as a partner.

**pudexacianinium chloride (ASP5354):** Added Stryker as a partner.